GDF11 (Growth Differentiation Factor 11) — Gene Therapy & Genetic Interventions
Circulating rejuvenation factor identified from parabiosis experiments that declines with age and may restore tissue function.
Overview
GDF11 is a TGF-beta superfamily member identified in heterochronic parabiosis experiments as a circulating factor that declines with age. Initial studies by the Wagers lab at Harvard demonstrated that GDF11 supplementation reversed age-related cardiac hypertrophy, improved muscle regeneration, enhanced neurogenesis, and restored cerebral vasculature in aged mice. However, subsequent studies produced conflicting results, with some groups reporting no benefit or even harm from GDF11 administration. The controversy centers on GDF11 vs. GDF8 (myostatin) assay specificity and dose-dependent effects. Elevian Inc. is developing GDF11-based therapies.
Indications
- Age-related cardiac hypertrophy (preclinical, controversial)
- Muscle regeneration in aging (preclinical, controversial)
- Neurogenesis and cognitive function (preclinical)
- Cerebrovascular function
- Stroke recovery (Elevian pipeline)
Mechanism of Action
GDF11 signals through ALK4/5/7 and ActRII/IIB receptors, activating Smad2/3 transcription factors
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Recombinant GDF11 | 0.1 mg/kg/day | Daily injection | Preclinical murine dose; human dose not established |
Evidence Grade
GRADE C
Safety & Contraindications
- Conflicting preclinical data on efficacy and safety
- High doses may cause muscle wasting (GDF11 is structurally similar to myostatin/GDF8)
- Dose-response relationship appears to have narrow therapeutic window
- Assay specificity issues complicate interpretation of prior studies
- Elevian Phase 1 trial for stroke initiated (2023)
- Long-term effects of exogenous GDF11 unknown